Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
Like many health care stakeholders, managed care pharmacy professionals applaud the accelerating pace of biopharmaceutical innovation. Medical research and development is bringing forward hundreds of new therapies that offer the promise of cures or “near-cures” for many of history’s most dreaded and deadly diseases.
This is great news for humanity. And it’s a testament to the remarkable work of the biopharmaceutical industry.
But it goes without saying that challenges remain. The key challenge for managed care pharmacy is how to ensure that needed products are broadly covered and widely available for patients in an era of constrained budgets. In other words, how can we continue to afford the many high-investment and high-cost therapies coming to market each year?
The challenge is compounded by the dynamic nature of our insurance system, in which patients may switch among carriers before the effects of a therapy are fully realized.
The Academy of Managed Care Pharmacy (AMCP) is working hard to address this challenge. It was the topic of our July Partnership Forum, Designing Benefits and Payment Models for Innovative, High-Investment Medications. The two-day event in Baltimore gathered insights and suggestions of more than 30 experts representing health plans, integrated delivery systems, pharmacy benefit managers, employers, national professional associations, the federal government and biopharmaceutical companies. We are also happy to note that PhRMA was one of the stakeholders providing input.
Participants agreed that developing new models will be imperative if we hope to maintain our health care system’s financial viability. Promising suggestions that emerged included the use of long-term annuity payments, reinsurance markets, performance-based payments and milestone contracting. But participants also agreed there is no “one-size-fits-all” approach to address the needs of all stakeholders and all emerging therapies.
Selecting the appropriate payment model will be driven by factors such as the number of patients affected by a disease, the payer size and whether a therapy is curative or addresses a chronic condition.
The forum also brought to light significant regulatory and policy issues that must be addressed to facilitate pilot programs around these models. Hurdles now include the Medicaid best price requirements and the federal Anti-Kickback Statute that constrain the use of value-based contracting and other innovative ideas. Participants agreed that safe harbors should be created to allow innovative and creative approaches to be piloted.
In addition, participants noted that stakeholders must have access to real-world evidence to evaluate the efficacy and safety of new therapies over time. The fact that patients frequently switch among payers, however, can constrain timeframes for payment contracts.
These ideas and more will be published in greater detail in an upcoming issue of the Journal of Managed Care & Specialty Pharmacy (JMCP). The “proceedings” document will include an overview of current financial payment models, specific challenges inherent in each model, a list of potential solutions and a list of legal, regulatory and operational hurdles that must be considered in development of solutions.
I am proud of the work AMCP does in bringing together stakeholders from across the health care spectrum to address tough challenges. Our Partnership Forums provide a safe environment in which we can set aside preconceived notions and develop consensus solutions that will ensure all patients receive the best health care possible.
Susan A. Cantrell, RPh, CAE, is CEO of the Academy of Managed Care Pharmacy.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Incomplete evaluations undermine patient access to transformational medicine
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
PhRMA presents research at ISPOR 2022
Innovative contracts continue to gain traction and improve quality of care
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
Growth in innovative, value-based contracts holds promise for the health system and for patients
Innovative contracts drive access for patients and value for the system
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Low-value health care costs $345B each year and provides little benefit
Addressing barriers that inhibit value-based contracts
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
5 Ways to improve ICER’s value assessment framework
Assessing value top of mind at ISPOR 2019
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
Value assessments should include all the outcomes that matter to patients and families
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
Number of value-based contracts continues to rise
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
How ICER’s assessment of a new class of migraine treatments fails patients
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
Event tomorrow: Improving patient access to lifesaving medicines
Reality check: Value-based contracts are good for patients
Video: Barriers to results-based contracts
Improving care quality by engaging patients in shared decision making
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
Clarity around anti-kickback statute needed to promote innovative payment arrangements
Video: What is a results-based contract?
PhRMA Foundation recognizes inaugural Challenge Award recipients
Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care
The journey to better health care requires a holistic view
Medicare Monday: How Part B has evolved over the years
Modernizing FDA regulations to advance a value-driven health care system
PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines
ICYMI: Avalere and FasterCures develop new value framework from patient perspective
ICYMI: Innovative payment models helping provide patient access to new medicines
RA medicines often demonstrate far greater benefits to patients than initially understood
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
The Value Collaborative
Value-Driven Health Care
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
Guest post: Developing new payment models to ensure patients have access to high-investment therapies